Brief: Tarsus Pharmaceuticals Q2 EPS USD -0.48

Tarsus Pharmaceuticals

06/08/2025 21:05

Overview

Tarsus Q2 revenue rises 152% yr/yr to $102.7 mln, beating analyst expectations

Net loss for Q2 narrows to $20.3 mln from $33.3 mln last year

Co's DTC campaign boosts XDEMVY prescriptions and prescriber base significantly

Outlook

Tarsus expects peak potential of XDEMVY to exceed initial expectations

Company plans Phase 2 study for TP-04 in H2 2025

Tarsus to initiate Phase 2 study for TP-05 in 2026

Company anticipates European approval for XDEMVY in 2027

Result Drivers

XDEMVY SALES - Record net product sales of $102.7 mln, up 152% yr/yr, driven by strong demand and prescriber growth

DTC CAMPAIGN - Direct-to-consumer advertising significantly increased prescriptions and prescriber base

PRESCRIBER EXPANSION - Over 20,000 Eye Care Professionals now prescribing XDEMVY, exceeding initial targets

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$102.66 mln
$95.70 mln (6 Analysts)
Q2 EPS
-$0.48
Q2 Net Income
-$20.34 mln
Q2 Basic EPS
-$0.48
Q2 Operating Expenses
$124.84 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Tarsus Pharmaceuticals Inc is $72.00, about 42.8% above its August 5 closing price of $41.15

Press Release: ID:nGNX7lXpmH

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)